SuperworthP3 Health Partners price to sales ratio PIII
Market value divided by revenue over the last twelve months, since 2023.
- Today, Oct 23, 2026
- 0.0×
- 4-year median
- 2.5×
- Against its 4-year history
- 11th
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 0.0× to 68.8×
- Peer median
- 1.4×
P3 Health Partners' price to sales ratio is 0.0× as of Oct 23, 2026.
That is below its 4-year median of 2.5×, lower than on 89% of days in the last 4 years.
Over that time it ranged from 0.0× in Jan 2026 to 68.8× in Jun 2023.
The median for 10 healthcare stocks of a similar size is 1.4×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.0× | 0.0× | 0.1× |
| 2025 | 0.0× | 0.0× | 3.0× |
| 2024 | 2.4× | 2.4× | 17.4× |
| 2023 | 18.7× | 11.6× | 68.8× |
Against its peers
Companies in Healthcare nearest P3 Health Partners' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| PIIIP3 Health Partners | 0.0× |
| NEPHNephros | 1.9× |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 0.9× |
| SPROSpero Therapeutics | 1.4× |
| LFVNLifevantage | 0.4× |
| ICCCImmucell | 3.0× |
| KEQUKewaunee Scientific | 0.3× |
| PDEXPro DEX | 2.6× |
| PLXProtalix BioTherapeutics | 2.5× |
| NATRNatures Sunshine Products | 0.4× |
| Peer median | 1.4× |
Where P3 Health Partners ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on P3 Health Partners
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.